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Context: 11β-hydroxylase deficiency is the second most common form of congenital adrenal hyperplasia.
Untreated, this enzyme deficiency leads to virilization, hypertension, and significant height impairment.
Patient: We describe a patient from abroad who first presented to us at age 7 years for follow-up of ambiguous genitalia.
He had been investigated and treated in Pakistan at 3-years-of-age following presentation for bilateral cryptorchidism. He
was found to have 46, XX karyotype, elevated 17-OH progesterone and was diagnosed with congenital adrenal
hyperplasia. In Pakistan, the patient had abdominal hysterectomy, bilateral salpingoophrectomy, and was started on
corticosteroid replacement. At 7 years, shortly after immigrating to Canada, height was 138 cm and BMI 19.3 kg/m2
(+2.9 SDS and +1.7 SDS, respectively, male growth chart) and blood pressure was greater than the 99th percentile for age
and height. The patient had Prader stage III - IV genital anatomy. Bone age was significantly advanced, yielding a severely
compromised predicted final adult height. Biochemical evaluation was consistent with 11β-hydroxylase deficiency
congenital adrenal hyperplasia.
Intervention and outcome: In an attempt to improve final height, in addition to glucocorticoid replacement, this
patient was treated with recombinant growth hormone and a third generation aromatase inhibitor (Letrozole) with an
improvement in final height attained as compared with predicted height.
Conclusions: This case of a 46,XX patient raised as male with congenital adrenal hyperplasia due to 11β-hydroxylase
deficiency highlights a number of unique and difficult treatment challenges; specifically, the role of new therapeutic
options for optimization of growth in the context of prior suboptimal disease management.
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Congenital adrenal hyperplasia (CAH) due to 11β-
hydroxylase (11β-OH) deficiency is the second most com-
mon cause of CAH [1]. It accounts for approximately 5-8%
of all CAH cases and is caused by mutations in the
CYP11B1 gene [2]. The deficiency in 11β-OH results in a
buildup of 11-deoxycortisol and 11-deoxycorticosterone.
Clinical manifestations of CAH due to 11β-OH deficiency
include virilization and ambiguous genitalia in females. The
primary distinguishing feature between the more common
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unless otherwise stated.is the presence of hypertension and hypokalemia in the
latter.
Similar to CAH due to 21-OH deficiency, optimization of
height in CAH due to 11β-OH deficiency remains a diffi-
cult balance between suppressing adrenal androgen pro-
duction with corticosteroids and minimizing iatrogenic
effects of supra-physiologic corticosteroid treatment. As a
result, despite optimal treatment final adult height is often
impaired [3].
We report a case of a male-identifying, 46, XX, 11β-
OH deficiency CAH patient who presented to our ter-
tiary care center recently after immigration. At the initial
visit in our center, he had significantly compromised
projected final adult height. In this report we highlight
the significant response to height augmenting therapies,
namely a combination of growth hormone (GH) andntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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height in our patient.
Methods
Bone age assessment was independently assessed using
the Greulich and Pyle methodology [4]. Predictions of
final adult height were calculated use the Bayley and
Pinneau method [5]. Laboratory assessments were com-
pleted through locally available laboratory services.
Patient care was provided through outpatient pediatric
endocrinology clinic. All risks and benefits of interven-
tions were discussed with patient and family. Appropri-
ate consents were obtained for publication of this report.
Case presentation
A 7-year-old male patient of Pakistani descent and consan-
guineous parents (first cousins) presented with ambiguous
genitalia for evaluation to our endocrine clinic following
assessment of a younger sister. The younger sister had ini-
tially been found to have ambiguous genitalia and hyperten-
sion while being evaluated in the emergency department
for an intercurrent illness. The family had recently immi-
grated to Canada. The 7-year-old patient had initially re-
ceived evaluation and treatment at 3-years-of-age while in
Pakistan for bilateral cryptorchidism. At that time he was
found to have normal electrolytes, a 46, XX karyotype and
an elevated 17-OH progesterone (28 ng/mL; normal
<1 ng/mL). He was diagnosed there with non-salt wasting
CAH. The specific enzymatic deficiency was not delin-
eated. The patient underwent an abdominal hysterectomy
and bilateral salpingoophrectomy. He was started on
corticosteroid replacement prior to moving to North
America. According to his parents, follow-up was minimal
and no corticosteroid dose adjustment was made between
his initial presentation at 3 years and when he was first
seen in Canada at 7-years-of-age.
At 7 years, height was 137.5 cm (+2.9 S.D on male growth
curve) (see Figure 1) and blood pressure was greater than
the 99th percentile for age and height. The patient had
Prader stage III - IV genital anatomy and Tanner stage 1 pu-
bertal development. Baseline investigations demonstrated
elevated 17-OHP, 11-deoxycorticosterone, 11-deoxycortisol,
and suppressed plasma renin activity (See Table 1). There
was significant bone age advancement to 12 years (female
standard [4]; see Table 2), for chronological age of 7 years,
yielding a predicted final adult height of 152.6 cm (−3.3 S.D.
for a male) [4]. Findings were consistent with 11β-OH defi-
ciency CAH.
Intervention & results
The patient was treated with glucocorticoids while in
Pakistan, however, treatment was suboptimal. On initial
visit in Canada corticosteroid replacement was optimized
to a replacement dose of approximately 15 mg/m2/day ofhydrocortisone. Doses were adjusted as necessary and in-
creased to approximately 18–20 mg/m2/day of hydrocorti-
sone on average. This was subsequently changed to ~3.5
to 4.1 mg/m2/day of prednisone (using a bioequivalence
ratio of 5, this equates to 17.5 to 20.5 mg/m2/day of
hydrocortisone). Despite this treatment, ongoing bone-age
advancement and a slowing growth velocity to 4.2 cm/year
resulted in further diminishment of the projected adult
height to 150.4 cm (−3.7 S.D.).
After lengthy multidisciplinary discussions with the family
surrounding the ethical, social and ethnic considerations of
growth optimization, the decision to attempt growth aug-
mentation was undertaken. GH treatment (0.05 mg/kg/day;
6 days per week) was initiated at 8.3 years, which resulted in
an increase in growth velocity to 7.8 cm/year. However, in
response to continued bone age advancement, an AI, Letro-
zole (2.5 mg daily), was initiated at 9 years of age.
Blood pressure remained elevated despite glucocortic-
oid replacement and further treatment with Spironolac-
tone and Amlodipine were required for control. At age
12 the patient had insertion of testicular prosthesis. At
age 14 hypospadias repair and release of chordae was
performed. In addition, removal of breast tissue was per-
formed at this time as well. The patient was not initiated
on testosterone supplementation until completion of
growth as endogenous androgen production was deemed
to be adequate and to help maximize growth potential.
Of note, the circulating adrenal androgens were enough
to induce progressive pubertal changes such as axillary,
pubic and facial hair growth, voice changes and acne.
The patient had no adverse effects from GH or AI
treatment including no evidence of dysglycemia, dyslip-
idemia, hepatic dysfunction, vertebral malformations,
nor evidence of bone fragility. Letrozole and GH treat-
ment were continued until growth velocity was
negligible at 13.6 years of age. A final adult height of
167.5 cm (−1.3 S.D. male chart) was achieved (See
Figure 1). This represented an increase of 17.1 cm
(2.6 S.D.) when using female bone age standards or
16.4 cm (2.3 S.D.) when using male bone age standards
from the projected final adult height before introducing
GH and AI treatment (Table 2).
Discussion
A number of complex treatment issues arise in the man-
agement of patients with CAH. Issues such as gender-
identity, growth, blood pressure management, surgical
correction, and pubertal management are among the
clinical difficulties addressed by the multidisciplinary
medical team. The presented case illustrates a number
of these in a young patient with CAH due to 11β-OH
deficiency. Among these issues, in particular, we high-
light the unique aspects of optimizing height in this pa-







































Figure 1 Patient growth chart plotted on male growth chart depicting actual height and calculated predicted height using male
(diamond) and female (triangle) reference standards [4,5]. Parental heights are depicted with grey (mother) and black (father) arrows on the
right vertical axis. GH and Letrozole treatment duration depicted directly on the chart.
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adult height has not been thoroughly examined in the litera-
ture. While no reviews exist in 11β-OH deficiency, a recent
systematic review and meta-analysis of 21-OH deficiency
CAH demonstrated the final height S.D. score was – 1.38
(−1.56 to −1.20; I2 = 90.2%) in patients, despite optimizationTable 1 Laboratory investigations results at time of
presentation at 7 years of age
Test Value Reference range
Androstenedione (nM) 7.7 <2.0
Testosterone (nM) 2.2 <1.0
17-OH Progesterone (nM) 30.6 <6.0
11-Deoxycortisol (nM) 1580 <4.5
11-Deoxycorticosterone (nM) 40.3 <1.03
Plasma Renin Activity (ng/L/s) 0.15 >0.28of CAH treatment [6]. Optimization of height is often a deli-
cate balance between corticosteroid replacement to suppress
androgen excess while attempting to limit effects of gluco-
corticoid excess. The treatment of 11β-OH deficiency in-
volves achieving a similarly challenging balance. Although,
as demonstrated with the presented patient, CAH due to
11β-OH deficiency may require higher glucocorticoid doses
than those currently recommended for patients with CAH
due to 21-OH deficiency [7]. Patients with suboptimal con-
trol or inadequate treatment, such as our patient, may have
substantial reduction in their growth potential [3].
Current Endocrine Society guidelines do not endorse
the use of growth augmenting therapies outside of the
context of research studies [7]. Our case highlights the
success of these treatments in the setting of late diagno-
sis and initial suboptimal control leading to a significant
threat to final height attainment. While we do not
Table 2 Comparisons of final height estimations by male and female interpretations of bone age radiographs [4,5]
Chronological
age (years)
Height (cm) Female bone age (years) Estimated final height (cm) Male bone age (years) Estimated final height (cm)
7 137.5 12 152.6 14 151.9
8.5 144.8 13.5 150.4 15 151.1
9 149.6 13.5 155.3 15.5 154.1
9.5 152.6 13.5 158.5 15.5 157.2
10.6 157.8 13.5 163.9 15.5 162.5
11.8 162.4 14 167.1 16 165.7
12.8 165.1 16 166.3 17 166.8
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tain dire circumstances their use may be justified. Prior
to initiation of GH and Letrozole, our patient had a pre-
dicted adult height of 150.4 – 151.1 cm (depending on
female or male reference standard used respectively)
which increased by 16.4 – 17.1 cm by the time of attain-
ment of final adult height (167.5 cm; −1.3 S.D. male
standard). This final height is considerably greater than
these early predictions and also higher than his genetic
calculated mid-parental height for a female of 164 cm
(−1.8 S.D.). He received a total of 5.3 years of GH treat-
ment and 4.6 years of AI treatment. A recent prospect-
ive study of GH use in 21-OH deficiency CAH found a
final height gain of 9.2 ± 6.7 cm in males and 10.5 ±
3.7 cm in females with a mean GH treatment duration
of 5.6 ± 1.8 and 4.5 ± 1.6 years, respectively [8]. We
would advocate that in the setting of extreme impair-
ment of predicted final height, consideration of these
therapies may be beneficial. Similar to dosages used in
idiopathic short stature, we used a relatively high dose
of GH in our patient given the degree of predicted
growth impairment.
Our patient benefited from a combined therapeutic ap-
proach using corticosteroids, GH and aromatase inhib-
ition. Growth hormone treatment was initiated due to
ongoing impairments in predicted final adult height des-
pite corticosteroid treatment. While the GH treatment
had benefit in growth velocity (4.2 cm/year vs. 7.8 cm/year
respectively) further advancement in bone age continued
to compromise projected height benefit. The addition of
Letrozole, a third generation steroidal AI, to the treatment
regime resulted in dramatic benefit in final height by indu-
cing a slowing bone maturation. Over the span of approxi-
mately 2 years there was virtually no advancement of bone
maturation.
Aromatase inhibition has been used in an off-label
manner in a select group of pediatric conditions, includ-
ing hyperestrogenism, hyperandrogenism, pubertal gyne-
comastia and short stature [9]. Their use in CAH has
been limited. To date only one study has been con-
ducted examining the use of AIs for height augmenta-
tion in CAH [10]. In this trial, children were randomizedto 2 year treatment with 1) Flutamide, testolactone and
reduced hydrocortisone dose and fludrocortisone vs. 2)
Standard treatment with hydrocortisone and fludrocorti-
sone. The study demonstrated a slight trend to increased
predicted final adult height (+0.6 S.D.) in the testolac-
tone/flutamide group, however, the difference was not
statistically different. This trial has been ongoing and in
2004, subjects were switched to Letrozole; however, re-
sults have not yet been published [11].
The use of AIs in the pediatric setting must be used with
caution due to unknown potential long term complica-
tions and thus far only modest height benefits. In males
treated with AIs, hypertestosteronemia has been observed
[12]. This rise in serum testosterone is due to the reduced
estrogen feedback on the hypothalamus leading to in-
creased levels of LH. No adverse effects from hypertestos-
teronemia have been reported. In our patient, previous
oophorectomy and female karyotype obviated this risk. Of
interest, however, a slight increase in serum androgens
was noted with AI introduction. This increase would be
possible either through decreased conversion of androgens
or an increase in adrenal androgen production. Other po-
tential concerns with AI use have included impaired bone
mineral density, body composition and metabolic effects
such as dyslipidemias [9]. In addition, there is hesitancy in
using AIs in females due to concerns of undesirable effects
of hyperandrogenemia. In our patient, these potential ef-
fects were viewed as desirable due to his male gender
identification. Vertebral malformations have also been re-
ported to be associated with the use of AIs with particular
risk when used during the pre-puberty or early puberty
phases [13].
Various other growth augmenting therapies have been
explored in the setting of CAH with variable success. In
addition to standard therapy with glucocorticoids, these
have included growth hormone, GnRH analogs, and anti-
androgens to increase final height [14]. In our patient,
GnRH analogs would have been of no benefit given the
previous oophorectomy.
Of particular concern for our patient were the cultural
and societal implications of height attainment. Being raised
male, our patient had societal expectations of a higher final
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height in males is less drastic than in other species, it
remained an important factor for this family when deter-
mining treatment goals [15]. The notion that short stature
has a negative impact on psychosocial adaptation has been
disproved by recent studies done in healthy children [16].
However, in the context of short stature associated with a
chronic condition such as CAH, patient and family prefer-
ences may need to be considered. In particular, a patient
already stigmatized with having a chronic medical condi-
tion, gynecomastia, infertility, and abnormal genital anat-
omy, the normalization of height was an attainable and
beneficial goal for patient care.
While assessing bone maturation remains an important
tool in monitoring treatment in CAH [17], considerable dif-
ficulty exists in determining the most accurate method to
predict final adult height, particularly in patients such as
the one presented. Although our patient was raised as male,
he had a 46, XX karyotype. The endogenous androgen ex-
posure of our patient was significantly higher than that of
an otherwise healthy female. These exposures may have
significant influence on bone growth and development.
Thus, the interpretation of bone age radiography may be
difficult as the differential effect of chromosomal and hor-
monal influences are ultimately unknown. Interestingly,
despite significant variations in bone age interpretation
based on gender, the effect on final height prediction for
our patient was minimal (see Table 2 and Figure 1). Ultim-
ately, consistency with regard to interpretation of these
tests is paramount.
Conclusions
In summary, we present the growth response of a 46, XX
patient with CAH due to 11β-OH deficiency to final adult
height. Despite the significant impairment in predicted adult
height due to inadequate initial treatment, this patient dem-
onstrated favorable results with a combined therapeutic ap-
proach including the addition of GH and an AI to the
standard glucocorticoid treatment to optimized growth. Our
patient’s response to this regimen underscores the need for
further research into these new therapeutic avenues.
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